Springhill Fund Asset Management HK Co Ltd Invests $4.80 Million in Insmed Incorporated (NASDAQ:INSM)

Springhill Fund Asset Management HK Co Ltd purchased a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 69,500 shares of the biopharmaceutical company's stock, valued at approximately $4,798,000. Insmed makes up about 7.8% of Springhill Fund Asset Management HK Co Ltd's investment portfolio, making the stock its 5th biggest holding.

Several other hedge funds and other institutional investors also recently made changes to their positions in INSM. Norges Bank bought a new position in Insmed in the fourth quarter valued at about $126,606,000. Vanguard Group Inc. increased its holdings in Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Insmed by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock valued at $282,243,000 after buying an additional 273,759 shares during the period. Artisan Partners Limited Partnership grew its stake in Insmed by 8.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company's stock valued at $215,842,000 after acquiring an additional 242,242 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in shares of Insmed by 12.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock worth $136,648,000 after purchasing an additional 214,130 shares in the last quarter.

Insmed Stock Up 3.1 %

NASDAQ INSM traded up $1.99 during midday trading on Friday, hitting $66.80. 517,371 shares of the company traded hands, compared to its average volume of 2,266,786. The company has a market cap of $12.15 billion, a PE ratio of -11.93 and a beta of 1.07. The company's 50-day simple moving average is $76.45 and its 200-day simple moving average is $73.67. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million for the quarter, compared to analysts' expectations of $102.31 million. As a group, equities research analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on INSM shares. Guggenheim restated a "buy" rating and set a $101.00 price objective on shares of Insmed in a research note on Tuesday, February 25th. Wells Fargo & Company lifted their price objective on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. Stifel Nicolaus cut their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. Royal Bank of Canada restated an "outperform" rating and issued a $100.00 price objective on shares of Insmed in a research report on Wednesday, March 19th. Finally, Bank of America raised their price objective on shares of Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a research report on Thursday, March 20th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 18,750 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50. Following the transaction, the chief executive officer now owns 334,186 shares of the company's stock, valued at $25,742,347.58. This represents a 5.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Sara Bonstein sold 28,390 shares of the company's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total transaction of $2,296,751.00. Following the completion of the transaction, the chief financial officer now owns 155,506 shares in the company, valued at approximately $12,580,435.40. This represents a 15.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 499,613 shares of company stock valued at $39,569,355 over the last 90 days. 4.60% of the stock is currently owned by corporate insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.